Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform.
By clicking “I Agree”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
